GenVec, Inc. (Nasdaq:GNVC) announced today that the first human therapeutic clinical trial involving the company’s adenoviral-vector technology used in an HIV vaccine candidate will be conducted by the Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH) in Bethesda, MD. These will be the first human trials to assess the effectiveness of a “prime-boost” vaccine using GenVec’s adenovector technology as a potential therapy for patients infected with HIV. The randomized, placebo-controlled study will measure safety and immunogenicity, in 15 HIV positive patients.
